71 studies found for:    pasireotide
Show Display Options
Rank Status Study
1 Not yet recruiting Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical Treatment
Condition: Enterostomy
Interventions: Drug: Pasireotide;   Drug: Placebo
2 Active, not recruiting Pasireotide LAR and Pegvisomant Study in Acromegaly
Condition: Acromegaly
Interventions: Drug: Pasireotide LAR 60 mg;   Drug: Pegvisomant
3 Completed
Has Results
Somatostatin Analogue SOM230 (Pasireotide) in Healthy Male Volunteers
Condition: Hyperglycemia
Intervention: Drug: pasireotide
4 Recruiting Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.
Conditions: Cushing's Disease,;   Acromegaly,;   Neuroendocrine Tumors,;   Pituitary Tumors;   Ectopic ACTH Secreting (EAS) Tumors,;   Dumping Syndrome,;   Prostate Cancer,;   Melanoma Negative for bRAF,;   Melanoma Negative for nRAS
Intervention: Drug: Pasireotide
5 Completed Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)
Condition: Neuroendocrine Tumors
Intervention: Drug: Pasireotide LAR
6 Recruiting Pasireotide in Patients With Acromegaly Inadequately Controlled With First Generation Somatostatin Analogues
Condition: Acromegaly
Intervention: Drug: Pasireotide LAR
7 Active, not recruiting Pasireotide & Everolimus in Adult Patients With Radioiodine-Refractory Differentiated & Medullary Thyroid Cancer
Condition: Thyroid Cancer
Interventions: Drug: Everolimus;   Drug: Pasireotide;   Drug: Everolimus and Pasireotide
8 Completed Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function
Conditions: Hepatic Cirrhosis;   Alcoholism
Intervention: Drug: Pasireotide
9 Recruiting Pasireotide in Prevention of GI Toxicity
Condition: Hematological Malignancies
Interventions: Drug: Pasireotide + Chemo;   Drug: Pasireotide + Total Body Irradiation
10 Terminated Effect of Pasireotide Long Acting Release (LAR) on Gonadotroph Adenomas
Condition: Gonadotroph Adenomas
Intervention: Drug: pasireotide LAR
11 Recruiting Pasireotide LAR in Severe Polycystic Liver Disease
Conditions: Somatostatin Analogs;   Polycystic Liver Disease;   Autosomal Dominant Polycystic Kidney Disease;   Autosomal Dominant Polycystic Liver Disease
Interventions: Drug: Pasireotide LAR;   Drug: Placebo
12 Active, not recruiting Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease
Condition: Cushing's Disease
Intervention: Drug: Pasireotide with or without cabergoline
13 Terminated
Has Results
Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
Conditions: Pancreatic Neoplasm;   Pituitary Neoplasm;   Nelson Syndrome;   Ectopic ACTH Syndrome
Intervention: Drug: pasireotide LAR
14 Recruiting SOM230 Ectopic ACTH-producing Tumors
Condition: Ectopic ACTH Syndrome
Intervention: Drug: Pasireotide
15 Completed
Has Results
Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma
Condition: Advanced Adult Hepatocellular Carcinoma
Interventions: Drug: Everolimus;   Drug: Pasireotide
16 Active, not recruiting Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma
Condition: Hepatocellular Carcinoma
Intervention: Biological: SOM230
17 Unknown  Pasireotide LAR Administration in Lymphocele Prevention After Axillary Node Dissection for Breast Cancer
Condition: Breast Cancer
Interventions: Drug: PASIREOTIDE;   Drug: PLACEBO
18 Terminated Pasireotide (SOM230) With or Without Everolimus in Treating Patients With Hormone Resistant, Chemotherapy Naive Prostate Cancer
Conditions: Castrate Resistant Prostate Cancer;   Chemotherapy Naive Prostate Cancer;   Prostate Cancer
Interventions: Drug: Pasireotide;   Drug: Everolimus;   Other: Laboratory biomarker analysis
19 Completed Efficacy of Everolimus Alone or in Combination With Pasireotide LAR in Advanced PNET
Condition: Islet Cell Tumor
Interventions: Drug: Everolimus;   Drug: Pasireotide + Everolimus
20 Active, not recruiting 3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial
Condition: Neuroendocrine Carcinoma of the Lung and Thymus
Interventions: Drug: Pasireotide LAR;   Drug: Everolimus;   Drug: Pasireotide LAR + Everolimus

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years